Two-Pore-Domain K+ Channels Are a Novel Target for the Anesthetic Gases Xenon, Nitrous Oxide, and Cyclopropane

Molecular Pharmacology

Volumn 65, Issue 2, 2004, Pages 443-452

  Gruss, Marco ^a   Bushell, Trevor J ^a,b   Bright, Damian P ^a   Lieb, William R ^a   Mathie, Alistair ^a   Franks, Nicholas P ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF STRATHCLYDE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; CYCLOPROPANE; CYCLOPROPANE DERIVATIVE; GLUTAMATE RECEPTOR; GLUTAMINE; HALOTHANE; INHALATION ANESTHETIC AGENT; MEMBRANE PROTEIN; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NITROUS OXIDE; POTASSIUM CHANNEL; POTASSIUM CHANNEL PROTEIN TREK 1; POTASSIUM CHANNEL PROTEIN TREK-1; POTASSIUM ION; PROTEIN TASK3; PROTEIN TREK1; TASK 3 PROTEIN; TASK-3 PROTEIN; UNCLASSIFIED DRUG; VOLATILE AGENT; XENON;

ANESTHESIA MECHANISM; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL MEMBRANE POTENTIAL; CHANNEL GATING; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOPLASM; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG TARGETING; GENERAL ANESTHESIA; HUMAN; HUMAN CELL; HUMAN TISSUE; METABOLISM; METHODOLOGY; MOLECULAR DYNAMICS; PH MEASUREMENT; PHYSIOLOGY; POTASSIUM TRANSPORT; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FAMILY;

ANESTHETICS, INHALATION; CYCLOPROPANES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DELIVERY SYSTEMS; HUMANS; MEMBRANE POTENTIALS; NITROUS OXIDE; POTASSIUM CHANNELS; POTASSIUM CHANNELS, TANDEM PORE DOMAIN; XENON;

EID: 1642457188     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.65.2.443     Document Type: Article

References (41)

1. Antognini JF, Lewis BK, and Reitan JA (1994) Hypothermia minimally decreases nitrous oxide anesthetic requirements. Anesth Analg 79:980-982.
2. Chapman CG, Meadows HJ, Godden RJ, Campbell DA, Duckworth M, Kelsell RE, Murdock PR, Randall AD, Rennie GI, and Gloger IS (2000) Cloning, localisation and functional expression of a novel human, cerebellum specific, two pore domain potassium channel. Brain Res Mol Brain Res 82:74-83.
3. Cullen SC, Eger II EI, Cullen BF, and Gregory P (1969) Observations on the anesthetic effect of the combination of xenon and halothane. Anesthesiology 31:305-309.
4. de Sousa SL, Dickinson R, Lieb WR, and Franks NP (2000) Contrasting synaptic actions of the inhalational general anesthetics isoflurane and xenon. Anesthesiology 92:1055-1066.
5. + channels TREK-1 and TRAAK. Mol Pharmacol 57:906-912.
6. Dzoljic M and Van Duijn B (1998) Nitrous oxide-induced enhancement of gamma-aminobutyric acid A-mediated chloride currents in acutely dissociated hippocampal neurons. Anesthesiology 88:473-480.
7. Franks NP, Dickinson R, de Sousa SLM, Hall AC, and Lieb WR (1998) How does xenon produce anaesthesia? Nature (Lond) 396:32419.
8. + current. Nature (Lond) 333:662-664.
9. Franks NP and Lieb WR (1993) Selective actions of volatile general anaesthetics at molecular and cellular levels. Br J Anaesth 71:65-76.
10. Franks NP and Lieb WR (1994) Molecular and cellular mechanisms of general anaesthesia. Nature (Lond) 367:607-614.
11. Franks NP and Lieb WR (1996) Temperature dependence of the potency of volatile general anesthetics: implications for in vitro experiments. Anesthesiology 84:716-720.
12. + channels: an important target for volatile anesthetics? Nat Neurosci 2:395-396.
13. Gerstin KM, Gong DH, Abdallah M, Winegar BD, Eger EI, 2nd and Gray AT (2003) Mutation of KCNK5 or Kir3.2 potassium channels in mice does not change minimum alveolar anesthetic concentration. Anesth Analg 96:1345-1349.
14. Goldstein SA, Bockenhauer D, O'Kelly I, and Zilberberg N (2001) Potassium leak channels and the KCNK family of two-P-domain subunits. Nat Rev Neurosci 2:175-184.
15. + channel. Anesthesiology 88:1076-1084.
16. Hille B (2001) Ionic Channels of Excitable Membranes. Sinauer Associates Inc., Sunderland.
17. + channel TREK-1. EMBO (Eur Mol Biol Organ) J 21:2968-2976.
18. Hornbein TF, Eger EI, 2nd, Winter PM, Smith G, Wetstone D, and Smith KH (1982) The minimum alveolar concentration of nitrous oxide in man. Anesth Analg 61:553-556.
19. Jevtovic-Todorovic V, Todorovic SM, Mennerick S, Powell S, Dikranian K, Benshoff N, Zorumski CF, and Olney JW (1998) Nitrous oxide (laughing gas) is an NMDA antagonist, neuroprotectant and neurotoxin. Nat Med 4:460-463.
20. Lesage F (2003) Pharmacology of neuronal background potassium channels. Neuropharmacology 44:1-7.
21. + channel with multiple regulations by polyunsaturated fatty acids, lysophospholipids, and Gs, Gi and Gq protein-coupled receptors. J Biol Chem 275:28398-28405.
22. Ma D, Wilhelm S, Maze M, and Franks NP (2002) Neuroprotective and neurotoxic properties of the 'inert' gas, xenon. Br J Anaesth 89:739-746.
23. Maingret F, Patel AJ, Lesage F, Lazdunski M, and Honore E (1999) Mechano- or acid stimulation, two interactive modes of activation of the TREK-1 potassium channel. J Biol Chem 274:26691-26696.
24. Meadows HJ, Benham CD, Cairns W, Gloger I, Jennings C, Medhurst AD, Murdock P, and Chapman CG (2000) Cloning, localisation and functional expression of the human orthologue of the TREK-1 potassium channel. Pfleug Arch Eur J Physiol 439:714-722.
25. Mennerick S, Jevtovic-Todorovic V, Todorovic SM, Shen W, Olney JW, and Zorumski CF (1998) Effect of nitrous oxide on excitatory and inhibitory synaptic transmission in hippocampal cultures. J Neurosci 18:9716-9726.
26. Millar JA, Barratt L, Southan AP, Page KM, Fyffe RE, Robertson B, and Mathie A (2000) A functional role for the two-pore domain potassium channel TASK-1 in cerebellar granule neurons. Proc Natl Acad Sci USA 97:3614-3618.
27. Nicoll RA and Madison DV (1982) General anesthetics hyperpolarize neurons in the vertebrate central nervous system. Science (Wash DC) 217:1055-1057.
28. + channels. Anesthesiology 95:1013-1021.
29. + channels. Trends Neurosci 24:339-346.
30. + channels. Nat Neurosci 2:422-426.
31. Raines DE, Claycomb RJ, Scheller M, and Forman SA (2001) Nonhalogenated alkane anesthetics fail to potentiate agonist actions on two ligand-gated ion channels. Anesthesiology 95:470-477.
32. Raventós J (1956) The action of Fluothane-a new volatile anaesthetic. Br J Pharmacol Chemother 11:394-410.
33. Ries CR and Puil E (1999) Ionic mechanism of isoflurane's actions on thalamocortical neurons. J Neurophysiol 81:1802-1809.
34. Saidman LJ, Eger EI, 2nd, Munson ES, Babad AA, and Muallem M (1967) Minimum alveolar concentrations of methoxyflurane, halothane, ether and cyclopropane in man: correlation with theories of anesthesia. Anesthesiology 28:994-1002.
35. Sirois JE, Lei Q, Talley EM, Lynch C 3rd, and Bayliss DA (2000) The TASK-1 two-pore domain K+ channel is a molecular substrate for neuronal effects of inhalation anesthetics. J Neurosci 20:6347-6354.
36. Steward A, Allott PR, Cowles AL, and Mapleson WW (1973) Solubility coefficients for inhaled anaesthetics for water, oil and biological media. Br J Anaesth 45:282-293.
37. Talley EM and Bayliss DA (2002) Modulation of TASK-1 (Kcnk3) and TASK-3 (Kcnk9) potassium channels: volatile anesthetics and neurotransmitters share a molecular site of action. J Biol Chem 277:17733-17742.
38. Talley EM, Solorzano G, Lei Q, Kim D, and Bayliss DA (2001) Cns distribution of members of the two-pore-domain (KCNK) potassium channel family. J Neurosci 21:7491-7505.
39. Wilhelm S, Ma D, Maze M, and Franks NP (2002) Effects of xenon on in vitro and in vivo models of neuronal injury. Anesthesiology 96:1485-1491.
40. Yamakura T, Bertaccini E, Trudell JR, and Harris RA (2001) Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol 41:23-51.
41. Yamakura T and Harris RA (2000) Effects of gaseous anesthetics nitrous oxide and xenon on ligand-gated ion channels. Comparison with isoflurane and ethanol. Anesthesiology 93:1095-1101.